Profile data is unavailable for this security.
About the company
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Company’s research programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cell’s DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.
- Revenue in CAD (TTM)0.00
- Net income in CAD-2.94m
- Incorporated2019
- Employees--
- LocationRakovina Therapeutics Inc105 - 1008 Beach AvenueVancouver V6E 1T7CanadaCAN
- Phone+1 (604) 619-0225
- Fax+1 (604) 980-6264
- Websitehttps://www.rakovinatherapeutics.com/